In vitro to in vivo extrapolation of metabolic rate constants for physiologically based pharmacokinetic models

Toxicokinetics and Risk Assessment

Volumn , Issue , 2016, Pages 185-210

  Kedderis, Gregory L ^a  

^a Independent Investigator   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122905591     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Lehninger AL. Biochemistry: The Molecular Basis of Cell Structure and Function. 2nd ed. New York, NY: Worth, 1975.
2. Poyton RO. Memory and membranes: the expression of genetic and spatial memory during the assembly of organelle macrocompartments. Mod Cell Biol 1983; 2:15-72.
3. Clegg JS. Intracellular water and the cytomatrix: some methods of study and current views. J Cell Biol 1984; 99:167S-171S.
4. Clegg JS. Properties and metabolism of the aqueous cytoplasm and its boundaries. Am J Physiol 1984; 246:R133-R151.
5. Luby-Phelps K, Lanni F, Taylor DL. The submicroscopic properties of cytoplasm as a determinant of cellular function. Annu Rev Biophys Bio 1988; 17:369-396.
6. Segel IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York, NY: John Wiley & Sons, 1975.
7. Northrop DB. Fitting enzyme-kinetic data to V/K. Anal Biochem 1983; 132:457-461.
8. i for conventional and alternativesubstrate inhibitors. Biochem Pharmacol 1981; 30:1-7.
9. Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991; 266:10019-10022.
10. Cornish-Bowden A. Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides. FEBS Lett 1986; 203:3-6.
11. Fromm HJ. Summary of kinetic reaction mechanisms. Meth Enzymol 1979; 63:42-53.
12. Williams RT. Detoxication mechanisms: the metabolism and detoxication of drugs. In: Toxic Substances and Other Organic Compounds. 2nd ed. New York, NY: John Wiley & Sons, 1959.
13. Guengerich FP, Macdonald TL. Chemical mechanisms of catalysis by cytochromes P-450: a unified view. Acc Chem Res 1984; 17:9-16.
14. Porter TD, Coon MJ. Cytochrome P-450: multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 1991; 266:13469-13472.
15. Kedderis GL. The role of the mixed-function oxidase system in the toxication and detoxication of chemicals: relationship to chemical interactions. In: Goldstein RS, Hewitt WR, Hook JB, eds. Toxic Interactions. San Diego, CA: Academic, 1990:31-60.
16. White RE, Coon MJ. Oxygen activation by cytochrome P-450. Annu Rev Biochem 1980; 49:315-356.
17. Guengerich FP, Macdonald TL. Mechanisms of cytochrome P-450 catalysis. FASEB J 1990; 4:2453-2459.
18. Newcomb M, Hollenberg PF, Coon MJ. Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. Arch Biochem Biophys 2003; 409:72-79.
19. Hollenberg PF. Mechanisms of cytochrome P450 and peroxidase-catalyzed xenobiotic metabolism. FASEB J 1992; 6:686-694.
20. Hlavica P, Lewis DF. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. Eur J Biochem 2001; 268:4817-4835.
21. Atkins WM. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 2005; 45:291-310.
22. Houston JB, Galetin A. Modeling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 2005; 433:351-360.
23. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992; 54:17-61.
24. Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther 1992; 53:275-354.
25. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43:149-173.
26. Dahl AR, Hadley WM. Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit Rev Toxicol 1991; 21:345-372.
27. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967; 19:317-366.
28. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. Cancer Res 1982; 42:4875-4917.
29. Gustafsson JA, Mode A, Norstedt G, et al. Sex steroid induced changes in hepatic enzymes. Annu Rev Physiol 1983; 45:51-60.
30. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992; 6:724-730.
31. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4:391-407.
32. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993; 23:1-20.
33. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
34. Lewis DF. 57 varieties: the human cytochromes P450. Pharmacogenetics 2004; 5:305-318.
35. Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther 1993; 57:129-140.
36. Hines RN, Coshman JR, Philpot RM, et al. The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol Appl Pharmacol 1994; 125:1-6.
37. Jakoby WB, Zeigler DM. The enzymes of detoxication. J Biol Chem 1990; 265:20715-20718.
38. Cashman JR, Zhang J. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos 2002; 30:1043-1052.
39. Mannervik B, Danielson UH. Glutathione transferases-structure and catalytic activity. Crit Rev Biochem 1988; 23:283-337.
40. Pickett CB, Lu AY. Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Biochem 1989; 58:743-764.
41. Armstrong RN. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 1997; 10:2-18.
42. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990; 30:603-631.
43. Baillie TA, Slatter JG. Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo. Acc Chem Res 1991; 24:264-270.
44. Anders MW, Losh L, Dekant W, et al. Biosynthesis and biotransformation of glutathione S-conjugates to toxic metabolites. Crit Rev Toxicol 1988; 18:311-341.
45. Mulder GJ. Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 1992; 32:25-49.
46. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616.
47. Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984; 15:1213-1249.
48. Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 2000; 129:171-193.
49. Duffel MW et al. Enzymatic aspects of the phenol (aryl) sulfotransferases. Drug Metab Rev 2001; 33:369-395.
50. Negishi M, Pederson LG, Petrotchenko E, et al. Structure and function of sulfo-transferases. Arch Biochem Biophys 2001; 390:149.
51. Barr J, Weir AJ, Brendel K, et al. Liver slices in dynamic organ culture. I. An alternative in vitro technique for the study of rat hepatic drug metabolism. Xenobiotica 1991; 21:331-339.
52. Barr J, Weir AJ, Brendel K, et al. Liver slices in dynamic organ culture. II. An in vitro cellular technique for the study of integrated drug metabolism using human tissue. Xenobiotica 1991; 21:341-350.
53. Worboys PD, Brennon B, Bradburg A, et al. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes, and liver slices, with in vivo disposition. Xenobiotica 1996; 26:897-907.
54. Ekins S, Murray GI, Burke MD, et al. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metab Dispos 1995; 23:1274-1279.
55. Thohan S, Zurieh MC, Chung H, et al. Tissue slices revisited: evaluation and development of a short-term incubation for integrated drug metabolism. Drug Metab Dispos 2001; 29:1337-1342.
56. Billings RE, McMahon RE, Ashmore J, et al. The metabolism of drugs in isolated rat hepatocytes: a comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions. Drug Metab Dispos 1977; 5:518-526.
57. Sirica AE, Pitot HC. Drug metabolism and effects of carcinogens in cultured hepatic cells. Pharmacol Rev 1979; 31:205-228.
58. Guengerich FP. Analysis and characterization of enzymes. In: Hayes AW, ed. Principles and Methods of Toxicology. New York, NY: Raven Press, 1989:777-814.
59. Seglen PO, Gordon PB, Poli A. Amino acid inhibition of the autophagic/lysosomal pathway of protein degradation in isolated rat hepatocytes. Biochim Biophys Acta 1980; 630:103-118.
60. Gargas ML, Burgess RJ, Voisard DE, et al. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 1989; 98:87-99.
61. Jepson GW, Hoover DK, Black RK, et al. A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fund Appl Toxicol 1994; 22:519-524.
62. Artola-Garicano E, Vaes WHJ, Hermens JLM. Validation of negligible depletion solid-phase microextraction as a tool to determine tissue/blood partition coefficients for semivolatile and nonvolatile organic chemicals. Toxicol Appl Pharmacol 2000; 166:138-144.
63. Sjoholm I, Ekawan B, Kober A, et al. Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 1979; 16:767-777.
64. Teo SKO, Kedderis GL, Gargas ML. Determination of tissue partition coefficients for volatile tissue-reactive chemicals: acrylonitrile and its metabolite 2-cyanoethylene oxide. Toxicol Appl Pharmacol 1994; 128:92-96.
65. Kedderis GL, Carfagna MA, Held SD, et al. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharmacol 1993; 123:274-282.
66. Seglen PO. Preparation of isolated rat liver cells. Meth Cell Biol 1976; 13:29-83.
67. Arias IM, Popper H, Schachter D, et al. The Liver: Biology and Pathobiology. New York, NY: Raven Press, 1982.
68. Arms AD, Travis CC. Reference Physiological Parameters in Pharmacokinetic Modeling, EPA/600/6-88/004, NTIS PB88-196019. Washington: D.C.: U.S. Environmental Protection Agency, 1988.
69. Miners JO, Smith PA, Sofich MJ, et al. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 2004; 44:1-25.
70. Clewell HJ, Andersen ME. Physiologically based pharmacokinetic modeling and bioactivation of xenobiotics. Toxicol Ind Health 1994; 10:1-24.
71. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47:1469-1479.
72. Lin JH, Sugiyama Y, Awazu S, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biop 1982; 10:649-661.
73. Carfagna MA, Held SD, Kedderis GL. Furan-induced cytolethality in isolated rat hepatocytes: correspondence with in vivo dosimetry. Toxicol Appl Pharmacol 1993; 123:265-273.
74. Kedderis GL, Held SD. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol 1996; 140:124-130.
75. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75:1028-1040.
76. Kedderis GL. Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 1997; 107:109-121.
77. Wilkinson GR. Pharmacokinetics of drug disposition: hemodynamic considerations. Annu Rev Pharmacol 1975; 15:11-27.
78. Park BK, Kitteringham NR, Piromohamed M, et al. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996; 41:477-491.
79. Dedrick RL, Forrester DD. Blood flow limitations in interpreting Michaelis constants for ethanol oxidation in vivo. Biochem Pharmacol 1973; 22:1133-1140.
80. Lipscomb JC, Teuscler LK, Swartout J, et al. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal 2003; 23:1221-1238.
81. Snawder JE, Lipscomb JC. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications for risk assessment. Regul Toxicol Pharmacol 2000; 32:200-209.
82. Lipscomb JC, Garrett CM, Snawder JE. Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans. Toxicol Appl Pharmacol 1997; 142:311-318.